The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis
Open accessAbstract
BACKGROUND & AIMS We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for 48 weeks; n = 34) or no treatment (controls, n = 36). Ultrasonography (every 3 months) and computed tomography (every 6 months) were performed to check the portal vein axis. The primary outcome was prevention of PVT. Radiologists and hepatologists that assessed outcomes were blinded to group assignments. Analysis was by intention to treat. RESULTS At 48 weeks, none of the patients in the enoxaparin group had developed PVT, compared with 6 of 36 (16.6%) controls (P = .025). At 96 weeks, no patient developed PVT in the enoxaparin group, compared with 10 of 36 (27.7%) controls (P = .001). At the end of the follow-up period, 8.8% of patients in the enoxaparin group and 27.7% of controls developed PVT (P = .048). The actuarial probability of PVT was lower in the enoxaparin group (P = .006). Liver decompensation was less frequent among patients given enoxaparin (11.7%) than controls (59.4%) (P < .0001); overall values were 38.2% vs 83.0%, respectively (P < .0001). The actuarial probability of liver decompensation was lower in the enoxaparin group (P < .0001). Eight patients in the enoxaparin group and 13 controls died. The actuarial probability of survival was higher in the enoxaparin group (P = .020). No relevant side effects or hemorrhagic events were reported. CONCLUSIONS In a small randomized controlled trial, a 12-month course of enoxaparin was safe and effective in preventing PVT in patients with cirrhosis and a Child-Pugh score of 7-10. Enoxaparin appeared to delay the occurrence of hepatic decompensation and to improve survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
De, M. M., Blanco, M.-J., Márquez-Coello, M., Soto, M.-J., Fernández-Gutiérrez, C., Rodríguez-Ramos, C., & González, J. A. G. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02505.x · Cited by 16
RetractedCONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences
Lisman, T., & Porte, R. J. (2010) · Blood · doi:10.1182/blood-2010-02-261891 · Cited by 667
Parlesak, A., Schäfer, C., Schütz, T., Bode, J. C., & Bode, C. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80242-1 · Cited by 647
Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis
Amitrano, L., Anna Guardascione, M., Brancaccio, V., Margaglione, M., Manguso, F., Iannaccone, L., Grandone, E., & Balzano, A. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.01.001 · Cited by 582
Patients with acute on chronic liver failure display ‘sepsis-like’ immune paralysis
Wasmuth, H. E., Kunz, D., Yagmur, E., Timmer-Stranghöner, A., Vidacek, D., Siewert, E., Bach, J., Geier, A., Purucker, E. A., Gressner, A. M., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.10.019 · Cited by 539
Francoz, C., Belghiti, J., Vilgrain, V, Sommacale, D., Paradis, V, Condat, B., Denninger, M. H., Sauvanet, A., Valla, D., & Durand, F. (2005) · Gut · doi:10.1136/gut.2004.042796 · Cited by 536
Self-citationContinuation of Low-Dose Aspirin Therapy in Peptic Ulcer Bleeding: A Randomized Trial
Sung, J. J. Y., Lau, J. Y. W., Ching, J. Y. L., Wu, J. C. Y., Lee, Y. T., Chiu, P. W. Y., Leung, V. K. S., Wong, V. W. S., & Chan, F. K. L. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-1-201001050-00179 · Cited by 520
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A., Laleman, W., & Gines, P. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.024 · Cited by 2,905
Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60121-5 · Cited by 1,740
EASL Clinical Practice Guidelines: Vascular diseases of the liver
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.040 · Cited by 808
Northup, P. G., Garcia‐Pagan, J. C., Garcia‐Tsao, G., Intagliata, N. M., Superina, R. A., Roberts, L. N., Lisman, T., & Valla, D. C. (2021) · Hepatology · doi:10.1002/hep.31646 · Cited by 667
Self-citationNery, F., Chevret, S., Condat, B., de Raucourt, E., Boudaoud, L., Rautou, P., Plessier, A., Roulot, D., Chaffaut, C., Bourcier, V., et al. (2015) · Hepatology · doi:10.1002/hep.27546 · Cited by 456
Self-citationAGA Clinical Practice Update: Coagulation in Cirrhosis
O’Leary, J. G., Greenberg, C. S., Patton, H. M., & Caldwell, S. H. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.070 · Cited by 450
De Pietri, L., Bianchini, M., Montalti, R., De Maria, N., Di Maira, T., Begliomini, B., Gerunda, G. E., di Benedetto, F., Garcia‐Tsao, G., & Villa, E. (2016) · Hepatology · doi:10.1002/hep.28148 · Cited by 438
Self-citationEvidence-based clinical practice guidelines for Liver Cirrhosis 2020
Yoshiji, H., Nagoshi, S., Akahane, T., Asaoka, Y., Ueno, Y., Ogawa, K., Kawaguchi, T., Kurosaki, M., Sakaida, I., Shimizu, M., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01788-x · Cited by 422
Loffredo, L., Pastori, D., Farcomeni, A., & Violi, F. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.042 · Cited by 410
Intagliata, N. M., Caldwell, S. H., & Tripodi, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.265 · Cited by 364
Thrombin Generation Assay and Its Application in the Clinical Laboratory
Tripodi, A. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.248625 · Cited by 318
Management of the critically ill patient with cirrhosis: A multidisciplinary perspective
Nadim, M. K., Durand, F., Kellum, J. A., Levitsky, J., O’Leary, J. G., Karvellas, C. J., Bajaj, J. S., Davenport, A., Jalan, R., Angeli, P., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.019 · Cited by 297
Cirrhosis and its complications: Evidence based treatment
Nusrat, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i18.5442 · Cited by 285
Hepatic microcirculation and mechanisms of portal hypertension
Gracia-Sancho, J., Marrone, G., & Fernández-Iglesias, A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0097-3 · Cited by 274
Coagulation in liver disease: A guide for the clinician
Northup, P. G., & Caldwell, S. H. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.026 · Cited by 268
Bosch, J., Groszmann, R. J., & Shah, V. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.003 · Cited by 252
Hilscher, M. B., Sehrawat, T., Arab, J. P., Zeng, Z., Gao, J., Liu, M., Kostallari, E., Gao, Y., Simonetto, D. A., Yaqoob, U., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.013 · Cited by 240
Solà, E., Pose, E., Campion, D., Piano, S., Roux, O., Simon-Talero, M., Uschner, F., de Wit, K., Zaccherini, G., Alessandria, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.009 · Cited by 41
“9,11,26 Although age in fl uences prognosis and excluding older patients may seem reasonable, there is no objective data to decide which is the best cut-off to use as an upper limit of age.”
Vascular targets for the treatment of portal hypertension
Brusilovskaya, K., Königshofer, P., Schwabl, P., & Reiberger, T. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1693115 · Cited by 28
Yu, M., Li, X., Xu, L., Zheng, C., Pan, W., Chen, H., Liu, X., Zhang, X., & Zhang, J. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000513 · Cited by 19
Metadata
- Authors
- Villa, E., Cammà, C., Marietta, M., Luongo, M., Critelli, R., Colopi, S., Tata, C., Zecchini, R., Gitto, S., Petta, S., Lei, B., Bernabucci, V., Vukotic, R., De Maria, N., Schepis, F., Karampatou, A., Caporali, C., Simoni, L., Del Buono, M., Zambotto, B., Turola, E., Fornaciari, G., Schianchi, S., Ferrari, A., & Valla, D.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 143
- Issue
- 5
- Pages
- 1253-1260.e4
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1993340951
- Cited by
- 744
- References
- 26
- FWCI
- 26.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.